Mersana Therapeutics, Inc. (MRSN): Price and Financial Metrics
MRSN Price/Volume Stats
| Current price | $3.25 | 52-week high | $9.62 |
| Prev. close | $3.34 | 52-week low | $0.80 |
| Day low | $3.18 | Volume | 2,390,300 |
| Day high | $3.35 | Avg. volume | 2,208,297 |
| 50-day MA | $4.46 | Dividend yield | N/A |
| 200-day MA | $2.58 | Market Cap | 394.23M |
MRSN Stock Price Chart Interactive Chart >
Mersana Therapeutics, Inc. (MRSN) Company Bio
Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patients’ lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.
Latest MRSN News From Around the Web
Below are the latest news stories about MERSANA THERAPEUTICS INC that investors may wish to consider to help them evaluate MRSN as an investment opportunity.
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on December 1, 2023, the Compensation Committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 12,205 shares of its common |
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2023 Earnings Call TranscriptMersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2023 Earnings Call Transcript November 7, 2023 Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.31. Operator: Good morning, and welcome to the Mersana Therapeutics Third Quarter 2023 Conference Call and Webcast. [Operator Instructions]. Please note, this call is being recorded. I would now like to […] |
Q3 2023 Mersana Therapeutics Inc Earnings CallQ3 2023 Mersana Therapeutics Inc Earnings Call |
Mersana Therapeutics Inc (MRSN) Reports Q3 2023 Financial ResultsCompany's Q3 2023 Earnings Highlight Progress in Clinical Trials and Strategic Priorities |
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial ResultsAdvancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana’s B7-H4 Dolasynthen ADCPreparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana’s HER2 Immunosynthen ADCCapital resources expected to support current operating plan commitments into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering a |
MRSN Price Returns
| 1-mo | -32.85% |
| 3-mo | 19.93% |
| 6-mo | 113.82% |
| 1-year | -23.35% |
| 3-year | -79.56% |
| 5-year | -27.13% |
| YTD | 40.09% |
| 2023 | -60.41% |
| 2022 | -5.79% |
| 2021 | -76.63% |
| 2020 | 364.40% |
| 2019 | 40.44% |
Continue Researching MRSN
Want to do more research on Mersana Therapeutics Inc's stock and its price? Try the links below:Mersana Therapeutics Inc (MRSN) Stock Price | Nasdaq
Mersana Therapeutics Inc (MRSN) Stock Quote, History and News - Yahoo Finance
Mersana Therapeutics Inc (MRSN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...